



Jan A. Alfheim  
CEO

# Oncoinvent AS



- Founded in 2010
- 3rd company started by serial entrepreneurs Dr. Roy H. Larsen and Professor Øyvind S. Bruland
- 19 fulltime employees, 3 Industrial PhDs, 2 part-time
- Own clinical product production facility



Dr. Roy H. Larsen, Ph.D.



Professor of clinical oncology Øyvind S. Bruland



Betalutin®



Radspherin®

# Radspherin<sup>®</sup>

alpha-emitting microparticles for local applications

## **SPECIALLY DESIGNED CaCO<sub>3</sub> microparticles**

- Carriers for the alpha-emitting isotope
- Degradable and non-toxic
- Regional retention, very little systemic exposure

## **A NEW alpha-emitting radioisotope Ra-224**

- High energetic radiation for efficient tumor cell kill
- Local deposition of radiation
- Therapeutic relevant temporal and spatial window
- Low probability of unintended radiation damage



# Radspherin® near-term development focus



NIH U.S. National Library of Medicine  
**ClinicalTrials.gov**  
Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

Home > Search Results > Study Record Detail

Trial record 1 of 2 for: oncoinvent

Previous Study | Return to List | Next Study ▾

### Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

ClinicalTrials.gov Identifier: NCT03732781

**⚠** The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

**Recruitment Status** ⓘ : Not yet recruiting  
**First Posted** ⓘ : November 7, 2018  
**Last Update Posted** ⓘ : November 27, 2018  
[See Contacts and Locations](#)

**Sponsor:**  
Oncoinvent AS

**Information provided by (Responsible Party):**  
Oncoinvent AS

Study Details | **Tabular View** | No Results Posted | Disclaimer | How to Read a Study Record

#### Study Description

**Brief Summary:**

This is a phase 1 open label study to evaluate the dose, safety and tolerability of an IP o-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma following resection.

The study consists of three different cohorts:

- Dose escalation cohorts (Phase 1a)
- Repeated injection cohorts (Phase 1b)
- Fulminant cohort

NIH U.S. National Library of Medicine  
**ClinicalTrials.gov**  
Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

Home > Search Results > Study Record Detail Save this study

Trial record 2 of 2 for: oncoinvent

Previous Study | Return to List | Next Study

### Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

ClinicalTrials.gov Identifier: NCT03732768

**⚠** The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

**Recruitment Status** ⓘ : Not yet recruiting  
**First Posted** ⓘ : November 7, 2018  
**Last Update Posted** ⓘ : November 27, 2018  
[See Contacts and Locations](#)

**Sponsor:**  
Oncoinvent AS

**Information provided by (Responsible Party):**  
Oncoinvent AS

Study Details | **Tabular View** | No Results Posted | Disclaimer | How to Read a Study Record

#### Study Description

**Brief Summary:**

RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose Limiting Toxicities (which will stop the dose escalation), this will be the recommended dose for further exploration. Acceptability of up to 7 MBq gives the opportunity to explore the doses of the dose escalation split into two administrations, and given as two separate injections 1 week apart. Split doses of 1, 2 and 3.5 MBq will be administered as two injections. Each subject will be followed until disease progression (in the abdominal cavity), or for 12 months after the administration of Radspherin® (whichever comes first).

# Peritoneal carcinomatosis

	Estimated incidence in 2018*	Estimated prevalence in 2018*	Estimated new cases with peritoneal carcinomatosis
Ovarian cancer (all types in 7 MM)	71 471	217 263	50 029 (70%)
Colorectal cancer (in 8 MM)	791 057	2 740 594	237 317 (30%)




Malignant ascites is a serious condition commonly related to PC

**Peritoneal carcinomatosis is the most common terminal feature of ovarian cancer**

## ICC showcase & BIO 2019 objective

- To meet potential new investors and potential new partners
- To build awareness around Oncoinvent AS and our promising new therapeutic Radspherin<sup>®</sup> with a view to future financing activities next year



# Innovations for better cancer care



Thank you for your attention